The Hallucinogen DOI Reduces Low-Frequency Oscillations in Rat Prefrontal Cortex: Reversal by Antipsychotic Drugs

Biological Psychiatry

Volumn 64, Issue 5, 2008, Pages 392-400

  Celada, Pau ^a   Puig, M Victoria ^a   Díaz Mataix, Llorenç ^a   Artigas, Francesc ^a  

^a CSIC   (Spain)

Author keywords

5 HT2A receptors; EEG; local field potential; psychotomimetic agents; pyramidal neurons; schizophrenia

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; CLOZAPINE; HALOPERIDOL; PSYCHEDELIC AGENT; VOLINANSERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; ELECTRIC POTENTIAL; ELECTROLYSIS; INFORMATION PROCESSING; MALE; NERVE CELL NETWORK; NONHUMAN; OSCILLATION; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SCHIZOPHRENIA; SYMPTOM; THALAMUS NUCLEUS; WISTAR RAT;

ACTION POTENTIALS; AMPHETAMINES; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BIOLOGICAL CLOCKS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; ELECTROLYSIS; EVOKED POTENTIALS; FLUOROBENZENES; FOURIER ANALYSIS; HALLUCINOGENS; MALE; NEURONS; PIPERIDINES; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SEROTONIN ANTAGONISTS; THALAMUS;

EID: 48949088465     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.03.013     Document Type: Article

References (75)

1. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122 (1999) 593-624
2. Selemon L.D., and Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 45 (1999) 17-25
3. Lewis D.A., and Lieberman J.A. Catching up on schizophrenia: Natural history and neurobiology. Neuron 28 (2000) 325-334
4. Weinberger D.R., Egan M.F., Bertolino A., Callicott J.H., Mattay V.S., Lipska B.K., et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50 (2001) 825-844
5. Lewis D.A., Hashimoto T., and Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6 (2005) 312-324
6. Fuster J.M. The Prefrontal Cortex. Anatomy, Physiology and Neuropsychology of the Frontal Lobe (1997), Lippincott-Raven, New York
7. Miller E.K., and Cohen J.D. An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24 (2001) 167-202
8. Elvevag B., and Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14 (2000) 1-21
9. Akil M., Edgar C.L., Pierri J.N., Casali S., and Lewis D.A. Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biol Psychiatry 47 (2000) 361-370
10. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22 (2002) 3708-3719
11. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1 (1988) 179-186
12. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93 (1996) 9235-9240
13. Egan M.F., and Weinberger D.R. Neurobiology of schizophrenia. Curr Opin Neurobiol 7 (1997) 701-707
14. Kapur S. How antipsychotics become anti-"psychotic"-from dopamine to salience to psychosis. Trends Pharmacol Sci 8 (2004) 402-406
15. Kornetsky C., and Markowitz R. Animal models of schizophrenia. In: Lipton M.A., DiMascio, and Killam A.K.F. (Eds). Psychopharmacology: A Generation of Progress (1978) 583-593
16. Ellenbroek B.A., and Cools A.R. Animal models with construct validity for schizophrenia. Behav Pharmacol 1 (1990) 469-490
17. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
18. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., and Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology (Berl) 169 (2003) 215-233
19. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Melson A.K., Hershey T., et al. Ketamine-induced NMDA receptor hypofunction as model of memory impairment and psychosis. Neuropsychopharmacology 20 (1999) 106-118
20. Nichols D.E. Hallucinogens. Pharmacol Ther 101 (2004) 131-181
21. Schreiber R., Brocco M., and Millan M.J. Blockade of the discriminative stimulus effects of DOI by MDL 100907 and the "atypical" antipsychotics, clozapine and risperidone. Eur J Pharmacol 264 (1994) 99-102
22. Martín-Ruiz R., Puig M.V., Celada P., Shapiro D.A., Roth B.L., Mengod G., and Artigas F. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 21 (2001) 9856-9866
23. 2A receptors: Relationship to thalamocortical afferents. Cereb Cortex 13 (2003) 870-882
24. Aghajanian G.K., and Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36 (1997) 589-599
25. 2A receptors, increases EPSCs in layer v pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825 (1999) 161-171
26. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40 (1991) 399-412
27. Villalobos C., Beique J.C., Gingrich J.A., and Andrade R. Serotonergic regulation of calcium-activated potassium currents in rodent prefrontal cortex. Eur J Neurosci 22 (2005) 1120-1126
28. 2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex 14 (2004) 281-299
29. Puig M.V., Artigas F., and Celada P. Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: Involvement of serotonin and GABA. Cereb Cortex 15 (2005) 1-14
30. Kargieman L., Santana N., Mengod G., Celada P., and Artigas F. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci U S A 104 (2007) 14843-14848
31. Fuller J.H., and Schlag J.D. Determination of antidromic excitation by the collision test: problems of interpretation. Brain Res 112 (1976) 283-298
32. Berendse H.W., and Groenewegen H.J. Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat. Neuroscience 42 (1991) 73-102
33. Van der Werf Y.D., Witter M.P., and Groenewegen H.J. The intralaminar and midline nuclei of the thalamus. Anatomical and functional evidence for participation in processes of arousal and awareness. Brain Res Rev 39 (2002) 107-140
34. Laviolette S.R., Lipski W.J., and Grace A.A. A subpopulation of neurons in the medial prefrontal cortex encodes emotional learning with burst and frequency codes through a dopamine D4 receptor-dependent basolateral amygdala input. J Neurosci 25 (2005) 6066-6075
35. Lambe E.K., and Aghajanian G.K. Prefrontal cortical network activity: opposite effects of psychedelic hallucinogens and and D1/D5 receptor activation. Neuroscience 145 (2007) 900-910
36. Steriade M., McCormick D.A., and Sejnowski T.J. Thalamocortical oscillations in the sleeping and aroused brain. Science 262 (1993) 679-685
37. Contreras D., and Steriade M. Cellular basis of EEG slow rhythms: A study of dynamic corticothalamic relationships. J Neurosci 15 (1995) 604-622
38. Steriade M. Grouping of brain rhythms in corticothalamic systems. Neuroscience 137 (2006) 1087-1106
39. Mukovski M., Chauvette S., Timofeev I., and Volgushev M. Detection of active and silent states in neocortical neurons from the field potential signal during slow-wave sleep. Cereb Cortex 17 (2007) 400-414
40. Sanchez-Vives M.V., and McCormick D.A. Cellular and network mechanisms of rhythmic recurrent activity in neocortex. Nat Neurosci 3 (2000) 1027-1034
41. Steriade M., Nunez A., and Amzica F. Intracellular analysis of relations between the slow (<1 Hz) neocortical oscillation and other sleep rhythms of the electroencephalogram. J Neurosci 13 (1993) 3266-3283
42. Rigas P., and Castro-Alamancos M.A. Thalamocortical up states: Differential effects of intrinsic and extrinsic cortical inputs on persistent activity. J Neurosci 27 (2007) 4261-4272
43. Groenewegen H.J., and Uylings H.B. The prefrontal cortex and the integration of sensory, limbic and autonomic information. Prog Brain Res 126 (2000) 3-28
44. Gonzalez-Maeso J., Weisstaub N.V., Zhou M., Chan P., Ivic L., Ang R., et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53 (2007) 439-452
45. Béïque J.C., Imad M., Mladenovic L., Gingrich J.A., and Andrade R. Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A 104 (2007) 9870-9875
46. Marek G.J., Wright R.A., Gewitz J.C., and Schoepp D.D. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in neocortex. Neuroscience 105 (2001) 379-392
47. 2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 14 (2004) 1100-1109
48. Garratt J.C., Kidd E.J., Wright I.K., and Marsden C.A. Inhibition of 5-hydroxytryptamine neuronal activity by the 5-HT agonist, DOI. Eur J Pharmacol 199 (1991) 349-355
49. 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res 972 (2003) 216-221
50. 2A receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 95 (2005) 1597-1607
51. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 124 (1996) 57-73
52. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 (1996) 87-96
53. Arnt J., and Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics?. A review of the evidence. Neuropsychopharmacology 18 (1998) 63-101
54. Schotte A., Janssen P.F., Megens A.A., and Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 631 (1993) 191-202
55. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: Role in atypical antipsychotic action. J Neurosci 25 (2005) 10831-10843
56. 2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 38 (1999) 315-317
57. 2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res 888 (2001) 51-59
58. Tseng K.Y., Mallet N., Toreson K.L., Le Moine C., Gonon F., and O'Donnell P. Excitatory response of prefrontal cortical fast-spiking interneurons to ventral tegmental area stimulation in vivo. Synapse 59 (2006) 412-417
59. Peters Y., Barnhardt N.E., and O'Donnell P. Prefrontal cortical up states are synchronized with ventral tegmental area activity. Synapse 52 (2004) 143-152
60. Gao M., Liu C.L., Yang S., Jin G.Z., Bunney B.S., and Shi W.Z. Functional coupling between the prefrontal cortex and dopamine neurons in the ventral tegmental area. J Neurosci 27 (2007) 5414-5421
61. Hajos M. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol Sci 27 (2006) 391-398
62. Kwon J.S., O'Donnell B.F., Wallenstein G.V., Greene R.W., Hirayasu Y., Nestor P.G., et al. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch Gen Psychiatry 56 (1999) 1001-1005
63. Spencer K.M., Nestor P.G., Niznikiewicz M.A., Salisbury D.F., Shenton M.E., and McCarley R.W. Abnormal neural synchrony in schizophrenia. J Neurosci 23 (2003) 7407-7411
64. Uhlhaas P.J., Linden D.E., Singer W., Haenschel C., Lindner M., Maurer K., and Rodriguez E. Dysfunctional long-range coordination of neural activity during Gestalt perception in schizophrenia. J Neurosci 26 (2006) 8168-8175
65. Uhlhaas P.J., and Singer W. Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron 52 (2006) 155-168
66. Stickgold R. Sleep-dependent memory consolidation. Nature 437 (2005) 1272-1278
67. Stickgold R., Hobson J.A., Fosse R., and Fosse M. Sleep, learning, and dreams: Off-line memory reprocessing. Science 294 (2001) 1052-1057
68. Marshall L., Helgadottir H., Molle M., and Born J. Boosting slow oscillations during sleep potentiates memory. Nature 444 (2006) 610-613
69. Keshavan M.S., Reynolds III C.F., Miewald M.J., Montrose D.M., Sweeney J.A., Vasko Jr. R.C., and Kupfer D.J. Delta sleep deficits in schizophrenia: evidence from automated analyses of sleep data. Arch Gen Psychiatry 55 (1998) 443-448
70. Hoffmann R., Hendrickse W., Rush A.J., and Armitage R. Slow-wave activity during non-REM sleep in men with schizophrenia and major depressive disorders. Psychiatry Res 95 (2000) 215-225
71. Sekimoto M., Kato M., Watanabe T., Kajimura N., and Takahashi K. Reduced frontal asymmetry of delta waves during all-night sleep in schizophrenia. Schizophr Bull 33 (2007) 1307-1311
72. Begic D., Hotujac L., and Jokic-Begic N. Quantitative EEG in "positive" and "negative" schizophrenia. Acta Psychiatr Scand 101 (2000) 307-311
73. Riba J., Anderer P., Jane F., Saletu B., and Barbanoj M.J. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology 50 (2004) 89-101
74. Goto Y., and Grace A.A. Alterations in medial prefrontal cortical activity and plasticity in rats with disruption of cortical development. Biol Psychiatry 60 (2006) 1259-1267
75. 2A heteroceptors on thalamocortical glutamatergic neurons. J Neurosci 20 (2000) 8846-8852